Global Diffuse Large B Cell Lymphoma Drug Market, Dosage, Price & Clinical Pipeline Outlook 2024
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
“Global Diffuse Large B Cell Lymphoma Drug Market, Dosage, Price & Clinical Pipeline Outlook 2024” Report Highlights:
As Diffuse Large B-cell Lymphoma is rare hematological malignancy, due to small target patient-base, very few specific therapies were developed for its treatment. However, in the last decade, with the arrival of anti-CD20 monoclonal antibody Rituxan which gained a huge market success due to high market demand fueled the market for diffuse large b-cell lymphoma. Soon after that, pharmaceutical industry recognized the potential of this segment of the market considering that highly unmet medical needs and increasing demand of effective therapy will drive the market in this segment.
With the rise in incidence and mortality rates due to Diffuse Large B-cell lymphoma, researchers and pharmaceutical industry have shifted their focus to develop unique targeted therapies for this type of cancer. Recently, pharmaceutical industry has provided a wide range of targeted drugs for Diffuse Large B-cell Lymphoma. This scenario clearly indicates that diffuse large b-cell lymphoma market has grown exponentially in past decade.
Recently, conventional treatment options including cytotoxic chemotherapeutics including doxorubicin; cyclophosphamide; vincristine and prednisone were introduced in the market as combination therapies along with the immunotherapeutic Rituxan for treating Diffuse Large B-cell Lymphoma. Rituxan has gained much importance in the market both as monotherapy and a significant component of combination therapy by enhancing the survival of 41% patients to 65% patients with diffuse large b-cell lymphoma. However, in recent studies, few researchers have demonstrated that patients have developed resistance for Rituxan combination therapy over a long period of time.
Additionally, patent expiration of the popular drug Rituxan has induced the development and arrival of several Rituxan Biosimilars in the market which is again boosting the Diffuse Large B-cell Lymphoma market. Europe currently has nearly 5 and US has 3 marketed biosimilars of Rituxan. In spite of the commercialization of biosimilars, the sales of Rituxan are still increasing. Rituxan has successfully collected nearly US$ 32 Billion revenues cumulatively in past 3 years.
More recently Yescarta which is the second CAR-T cell therapy to be approved by US FDA has entered the market. Another recently approved therapy is Ibrutinib which is an advanced targeted therapy has been commercialized. Both of these therapies have a great potential to generate high revenues for the pharmaceutical companies due to high efficacy of these products. Nonetheless, the huge market acceptance of Rituxan encourages the researchers and pharmaceutical industry to explore new opportunities in the drug which can further enhance Rituxan market at a higher rate and contribute to the growth of diffuse large b-cell lymphoma market.
Rituxan has been approved as a combination therapy called Rituxan Hycela. In this therapy Rituxan has been combined with an enzymatic therapy called Hyaluronidase. Such approaches by using popular drugs aids in securing the market place of a popular drug and further enhancing the overall Diffuse Large B-cell lymphoma market. The diffuse large b-cell lymphoma market has experienced a huge progress in past four-five years and is expected to grow in the coming future.
The diffuse large-B cell lymphoma Market has shown an impressive growth in the market size with continuous approvals of several advanced therapies including immunotherapy, CAR-T cell therapy and targeted therapy. Development of such advanced therapies is indeed a result of huge investments and funding from public as well as private sectors and continuous efforts of educational institutes for high quality research and innovations. Additionally, increasing incidence of the disease has also fuelled the diffuse large b-cell lymphoma market significantly. This scenario clearly indicates that global diffuse large b-cell lymphoma market acquires a major portion of modern cancer therapy market with a wide variety of advanced therapies indicated for this disease.
As diffuse large b-cell lymphoma occurs commonly in older population, the market can be segmented into regions with high population above 65 years. Thus the diffuse large b-cell lymphoma market has higher potential in North America due to large ageing population and several active ongoing research studies in this region. Europe is dominant in terms of availability of products in the market including Rituxan biosimilars and other unique therapeutics for treating diffuse large b-cell lymphoma. Furthermore, China and Japan also show highly opportunistic diffuse large b-cell lymphoma market.
We have analyzed a wide variety of aspects related to Diffuse Large B-Cell Lymphoma Market including the funding, investment, ongoing researches and development and commercialization of new therapies for treating Diffuse Large B-cell Lymphoma. Additionally, our research also includes the data about costs, consumer-base and commercial status of marketed & potential Therapeutics for treating Diffuse Large B-cell Lymphoma by collecting information from multiple sources. Constitutively, the report interprets the real facts and figures suggesting a positive market outlook of diffuse large B-Cell Lymphoma Market.
“Global Diffuse Large B Cell Lymphoma Drug Market, Dosage, Price & Clinical Pipeline Outlook 2024” Report Highlights:
- Price & Dosage Analysis of Commercially Available Drugs
- Patent, Price & Dosage Analysis of Recently Approved Drugs
- Market Analysis of Diffuse Large B Cell Lymphoma
- Market Sales Opportunity till 2024
- Global Diffuse Large B Cell Lymphoma Clinical Pipeline: 84 Drugs
- Marketed Global Diffuse Large B Cell Lymphoma Clinical Insight
As Diffuse Large B-cell Lymphoma is rare hematological malignancy, due to small target patient-base, very few specific therapies were developed for its treatment. However, in the last decade, with the arrival of anti-CD20 monoclonal antibody Rituxan which gained a huge market success due to high market demand fueled the market for diffuse large b-cell lymphoma. Soon after that, pharmaceutical industry recognized the potential of this segment of the market considering that highly unmet medical needs and increasing demand of effective therapy will drive the market in this segment.
With the rise in incidence and mortality rates due to Diffuse Large B-cell lymphoma, researchers and pharmaceutical industry have shifted their focus to develop unique targeted therapies for this type of cancer. Recently, pharmaceutical industry has provided a wide range of targeted drugs for Diffuse Large B-cell Lymphoma. This scenario clearly indicates that diffuse large b-cell lymphoma market has grown exponentially in past decade.
Recently, conventional treatment options including cytotoxic chemotherapeutics including doxorubicin; cyclophosphamide; vincristine and prednisone were introduced in the market as combination therapies along with the immunotherapeutic Rituxan for treating Diffuse Large B-cell Lymphoma. Rituxan has gained much importance in the market both as monotherapy and a significant component of combination therapy by enhancing the survival of 41% patients to 65% patients with diffuse large b-cell lymphoma. However, in recent studies, few researchers have demonstrated that patients have developed resistance for Rituxan combination therapy over a long period of time.
Additionally, patent expiration of the popular drug Rituxan has induced the development and arrival of several Rituxan Biosimilars in the market which is again boosting the Diffuse Large B-cell Lymphoma market. Europe currently has nearly 5 and US has 3 marketed biosimilars of Rituxan. In spite of the commercialization of biosimilars, the sales of Rituxan are still increasing. Rituxan has successfully collected nearly US$ 32 Billion revenues cumulatively in past 3 years.
More recently Yescarta which is the second CAR-T cell therapy to be approved by US FDA has entered the market. Another recently approved therapy is Ibrutinib which is an advanced targeted therapy has been commercialized. Both of these therapies have a great potential to generate high revenues for the pharmaceutical companies due to high efficacy of these products. Nonetheless, the huge market acceptance of Rituxan encourages the researchers and pharmaceutical industry to explore new opportunities in the drug which can further enhance Rituxan market at a higher rate and contribute to the growth of diffuse large b-cell lymphoma market.
Rituxan has been approved as a combination therapy called Rituxan Hycela. In this therapy Rituxan has been combined with an enzymatic therapy called Hyaluronidase. Such approaches by using popular drugs aids in securing the market place of a popular drug and further enhancing the overall Diffuse Large B-cell lymphoma market. The diffuse large b-cell lymphoma market has experienced a huge progress in past four-five years and is expected to grow in the coming future.
The diffuse large-B cell lymphoma Market has shown an impressive growth in the market size with continuous approvals of several advanced therapies including immunotherapy, CAR-T cell therapy and targeted therapy. Development of such advanced therapies is indeed a result of huge investments and funding from public as well as private sectors and continuous efforts of educational institutes for high quality research and innovations. Additionally, increasing incidence of the disease has also fuelled the diffuse large b-cell lymphoma market significantly. This scenario clearly indicates that global diffuse large b-cell lymphoma market acquires a major portion of modern cancer therapy market with a wide variety of advanced therapies indicated for this disease.
As diffuse large b-cell lymphoma occurs commonly in older population, the market can be segmented into regions with high population above 65 years. Thus the diffuse large b-cell lymphoma market has higher potential in North America due to large ageing population and several active ongoing research studies in this region. Europe is dominant in terms of availability of products in the market including Rituxan biosimilars and other unique therapeutics for treating diffuse large b-cell lymphoma. Furthermore, China and Japan also show highly opportunistic diffuse large b-cell lymphoma market.
We have analyzed a wide variety of aspects related to Diffuse Large B-Cell Lymphoma Market including the funding, investment, ongoing researches and development and commercialization of new therapies for treating Diffuse Large B-cell Lymphoma. Additionally, our research also includes the data about costs, consumer-base and commercial status of marketed & potential Therapeutics for treating Diffuse Large B-cell Lymphoma by collecting information from multiple sources. Constitutively, the report interprets the real facts and figures suggesting a positive market outlook of diffuse large B-Cell Lymphoma Market.
1. DIFFUSE LARGE B CELL LYMPHOMA
1.1 Introduction
1.2 Classification of Diffuse Large B Cell Lymphoma
2. MOLECULAR EVENTS INVOLVED IN DIFFUSE LARGE B CELL LYMPHOMA PATHOGENESIS
2.1 BCL6
2.2 BCL-2
2.3 MYC Gene
2.4 P53
3. MANAGEMENT APPROACHES FOR DIFFUSE LARGE B CELL LYMPHOMA
3.1 Diagnostic Approaches
3.1.1 Bone Marrow Biopsy Method
3.1.2 Positron Emission Tomography (PET)
3.2 Therapeutic Approaches
3.3 Radiation Therapy
4. PRICE & DOSAGE ANALYSIS OF COMMERCIALLY AVAILABLE DRUGS
4.1 Rituxan
4.2 Cyclophosphamide
4.3 Doxorubicin
4.4 Vincristine
4.5 Prednisone
5. PATENT, PRICE & DOSAGE ANALYSIS OF RECENTLY APPROVED DRUGS
5.1 Axicabtagene Ciloleucel (Yescarta)
5.2 Ibrutinib (Imbruvica)
5.3 Hyaluronidase
6. MARKET ANALYSIS OF DIFFUSE LARGE B CELL LYMPHOMA
6.1 Introduction to Lymphoma Disease
6.1.1 Market Exploration of Hodgkin Lymphoma
6.1.2 Market Size of Non-Hodgkin Lymphoma
6.2 Market Outlook of Diffuse Large B Cell Lymphoma
7. CURRENT TRENDS IN TREATMENT OF DIFFUSE LARGE B CELL LYMPHOMA
8. MARKET DYNAMICS OF DIFFUSE LARGE B CELL LYMPHOMA
8.1 Favorable Market Parameters
8.2 Commercialization Challenges
9. FUTURE PERSPECTIVE OF DIFFUSE LARGE B CELL LYMPHOMA
10. GLOBAL DIFFUSE LARGE B CELL LYMPHOMA CLINICAL PIPELINE BY COMPANY & PHASE
10.1 Global Diffuse large B Cell Lymphoma Pipeline Overview
10.2 Research
10.3 Preclinical
10.4 Clinical
10.5 Phase-I
10.6 Phase-I/II
10.7 Phase-II
10.8 Phase-III
10.9 Registered
10.10 Preregistration
11. MARKETED GLOBAL DIFFUSE LARGE B CELL LYMPHOMA CLINICAL INSIGHT BY COMPANY
11.1 Rituximab/Hyaluronidase (MabThera SC, RITUXAN SC & Rituxan Hycela)
11.2 Rituximab Biosimilar (Novex)
11.3 Rituximab Biosimilar (Maball)
12. COMPETITIVE LANDSCAPE
12.1 AbbVie
12.2 Arrien Pharmaceuticals
12.3 Aptose Biosciences
12.4 BeiGene
12.5 Celltrion
12.6 CTI BioPharma
12.7 Erytech Pharma
12.8 Hetero Drugs
12.9 Karyopharm Therapeutics
12.10 mAbxience
12.11 PIQUR Therapeutics
12.12 Philogen S.p.A.
12.13 Roche
12.14 Seattle Genetics
12.15 TG Therapeutics
1.1 Introduction
1.2 Classification of Diffuse Large B Cell Lymphoma
2. MOLECULAR EVENTS INVOLVED IN DIFFUSE LARGE B CELL LYMPHOMA PATHOGENESIS
2.1 BCL6
2.2 BCL-2
2.3 MYC Gene
2.4 P53
3. MANAGEMENT APPROACHES FOR DIFFUSE LARGE B CELL LYMPHOMA
3.1 Diagnostic Approaches
3.1.1 Bone Marrow Biopsy Method
3.1.2 Positron Emission Tomography (PET)
3.2 Therapeutic Approaches
3.3 Radiation Therapy
4. PRICE & DOSAGE ANALYSIS OF COMMERCIALLY AVAILABLE DRUGS
4.1 Rituxan
4.2 Cyclophosphamide
4.3 Doxorubicin
4.4 Vincristine
4.5 Prednisone
5. PATENT, PRICE & DOSAGE ANALYSIS OF RECENTLY APPROVED DRUGS
5.1 Axicabtagene Ciloleucel (Yescarta)
5.2 Ibrutinib (Imbruvica)
5.3 Hyaluronidase
6. MARKET ANALYSIS OF DIFFUSE LARGE B CELL LYMPHOMA
6.1 Introduction to Lymphoma Disease
6.1.1 Market Exploration of Hodgkin Lymphoma
6.1.2 Market Size of Non-Hodgkin Lymphoma
6.2 Market Outlook of Diffuse Large B Cell Lymphoma
7. CURRENT TRENDS IN TREATMENT OF DIFFUSE LARGE B CELL LYMPHOMA
8. MARKET DYNAMICS OF DIFFUSE LARGE B CELL LYMPHOMA
8.1 Favorable Market Parameters
8.2 Commercialization Challenges
9. FUTURE PERSPECTIVE OF DIFFUSE LARGE B CELL LYMPHOMA
10. GLOBAL DIFFUSE LARGE B CELL LYMPHOMA CLINICAL PIPELINE BY COMPANY & PHASE
10.1 Global Diffuse large B Cell Lymphoma Pipeline Overview
10.2 Research
10.3 Preclinical
10.4 Clinical
10.5 Phase-I
10.6 Phase-I/II
10.7 Phase-II
10.8 Phase-III
10.9 Registered
10.10 Preregistration
11. MARKETED GLOBAL DIFFUSE LARGE B CELL LYMPHOMA CLINICAL INSIGHT BY COMPANY
11.1 Rituximab/Hyaluronidase (MabThera SC, RITUXAN SC & Rituxan Hycela)
11.2 Rituximab Biosimilar (Novex)
11.3 Rituximab Biosimilar (Maball)
12. COMPETITIVE LANDSCAPE
12.1 AbbVie
12.2 Arrien Pharmaceuticals
12.3 Aptose Biosciences
12.4 BeiGene
12.5 Celltrion
12.6 CTI BioPharma
12.7 Erytech Pharma
12.8 Hetero Drugs
12.9 Karyopharm Therapeutics
12.10 mAbxience
12.11 PIQUR Therapeutics
12.12 Philogen S.p.A.
12.13 Roche
12.14 Seattle Genetics
12.15 TG Therapeutics
LIST OF FIGURES
Figure 1-1: Representation of T Lymphocytes & B Lymphocytes Cases of Non-Hodgkin Lymphoma (%)
Figure 1-2: Categorization of Diffuse Large B cell Lymphoma
Figure 2-1: Role of BCL6 Gene B Cell Differentiation for the Development of Diffuse Large B cell Lymphoma
Figure 2-2: Pathogenesis of Diffuse Large B cell Lymphoma by BCL-2 Oncogene
Figure 2-3: Involvement of MYC Gene in the Proliferation of Diffuse Large B cell Lymphoma
Figure 3-1: Diagnostic Methods of Diffuse Large B cell Lymphoma
Figure 4-1: Rituxan - Patent Approval Year & Expiration Year
Figure 4-2: Rituxan – Dose Schedule in a Cycle (by Number), 2018
Figure 4-3: Rituxan – Availability in Market by Vial Concentration (mg), 2018
Figure 4-4: Global - Rituxan Intravenous Solution Price by Concentration (10mg/mL) (US$/Unit), 2018
Figure 4-5: Rituxan – Price Analysis by Concentration (US$), 2018
Figure 4-6: Rituxan - Treatment Cost Analysis for Intravenous Route of Administration (US$), 2018
Figure 4-7: Global - Rituxan Sales (US$ Billion), 2015-2017
Figure 4-8: Cyclophosphamide - Available Intravenous Powder Concentration (mg/vial), 2018
Figure 4-9: Cyclophosphamide - Available Capsule Concentration (mg/vial), 2018
Figure 4-10: Cyclophosphamide – Dosage Analysis in Initial Treatment Course (mg/kg), 2018
Figure 4-11: Cyclophosphamide – Maximum Dose in Treatment Course (mg/kg), 2018
Figure 4-12: Cyclophosphamide – Dosage Analysis for Diffuse Large B- Cell Lymphoma (mg/m2/Day), 2018
Figure 4-13: Cyclophosphamide - Intravenous Powder Price Analysis by Concentration (mg), 2018
Figure 4-14: Cyclophosphamide - Capsule Price Analysis by Concentration (mg), 2018
Figure 4-15: Doxorubicin - Available Intravenous Powder Concentration (mg), 2018
Figure 4-16: Doxorubicin – Availability in Market by Vial Quantity (2mg/ml), 2018
Figure 4-17: Doxorubicin – Initial Dosage (mg/m2/Dose)
Figure 4-18: Doxorubicin – Maximum Dosage (mg/m2/Dose)
Figure 4-19: Doxorubicin – Duration of Treatment Cycle (Number of Days)
Figure 4-20: Doxorubicin - Intravenous Powder Price Analysis by Concentration (US$), 2018
Figure 4-21: Doxorubicin - Intravenous Solution Price Analysis by Concentration (US$), 2018
Figure 4-22: Vincristine – Dosage Analysis (mg/ml/Week)
Figure 4-23: Vincristine – Availability in Market by Vial Quantity (ml), 2018
Figure 4-24: Vincristine - Intravenous Solution Price Analysis by Concentration (US$), 2018
Figure 4-25: Prednisone – Available Oral Solution by Concentration (ml), 2018
Figure 4-26: Prednisone - Available Oral Tablet by Concentrations (mg), 2018
Figure 4-27: Prednisone - Oral Solution Price Analysis by Concentration (US$), 2018
Figure 4-28: Prednisone - Oral Tablet Cost Price Analysis (US$/100 Tablets), 2018
Figure 5-1: Yescarta – Patent Approval Year in US & Estimate Treatment Cost (US$)
Figure 5-2: Information of Yescarta Drug among the Population (%)
Figure 5-3: Imbruvica – US Patent Approval Year & Patent Expiration Year
Figure 5-4: Imbruvica - 140mg Capsule Price Analysis (US$/Packet), 2018
Figure 5-5: Imbruvica - Treatment Cost Analysis (US$), 2018
Figure 5-6: Imbruvica – Clinical Efficacy by Survival Rate & Survival Response (%), 2018
Figure 5-7: Imbruvica - Global Sales (US$ Billion), 2015 - 2017
Figure 5-8: Rituxan Hycela – Availability by Concentration (ml), 2018
Figure 5-9: Rituxan Hycela – Cell Units in Vial (by Number), 2018
Figure 5-10: Rituxan Hycela – Dosage in CHOP Therapy (mg/Cell Units), 2018
Figure 5-11: Rituxan Hycela – Price Analysis by Concentration (US$/Unit), 2018
Figure 5-12: Rituxan Hycela – Vial Price Analysis (US$), 2018
Figure 6-1: Global - Estimated Number of All New Annual Cancer Cases (%), 2018
Figure 6-2: Estimated New Annual Cases of Blood Cancers, 2018 (%)
Figure 6-3: Distribution of Types of Lymphoma (%)
Figure 6-4: Global - Hodgkin Lymphoma Market Opportunity (US$ Billion), 2017-2024
Figure 6-5: Global- Non-Hodgkin Lymphoma Market Growth Estimation (US$ Billion), 2017-2024
Figure 6-6: Classification of Subtypes of Non-Hodgkin Lymphoma Market (%)
Figure 6-7: Global - Patients Affected by Issues Before, During & After the Treatment (%), 2016
Figure 6-8: Barriers to Adequate Treatment Approach of Diffuse Large B cell Lymphoma (%), 2016
Figure 8-1: Favorable Factors for the Growth of Diffuse Large B cell Lymphoma Market
Figure 8-2: Challenges to the Growth of Diffuse Large B cell Lymphoma Market
Figure 10-1: Global Diffuse Large B Cell Lymphoma Clinical Pipeline by Phase (%), 2018 till 2024
Figure 10-2: Global Diffuse Large B Cell Lymphoma Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 10-3: Global Diffuse Large B Cell Lymphoma Clinical Pipeline by Phase (%),2018 till 2024
Figure 10-4: Global Diffuse Large B Cell Lymphoma Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 1-1: Representation of T Lymphocytes & B Lymphocytes Cases of Non-Hodgkin Lymphoma (%)
Figure 1-2: Categorization of Diffuse Large B cell Lymphoma
Figure 2-1: Role of BCL6 Gene B Cell Differentiation for the Development of Diffuse Large B cell Lymphoma
Figure 2-2: Pathogenesis of Diffuse Large B cell Lymphoma by BCL-2 Oncogene
Figure 2-3: Involvement of MYC Gene in the Proliferation of Diffuse Large B cell Lymphoma
Figure 3-1: Diagnostic Methods of Diffuse Large B cell Lymphoma
Figure 4-1: Rituxan - Patent Approval Year & Expiration Year
Figure 4-2: Rituxan – Dose Schedule in a Cycle (by Number), 2018
Figure 4-3: Rituxan – Availability in Market by Vial Concentration (mg), 2018
Figure 4-4: Global - Rituxan Intravenous Solution Price by Concentration (10mg/mL) (US$/Unit), 2018
Figure 4-5: Rituxan – Price Analysis by Concentration (US$), 2018
Figure 4-6: Rituxan - Treatment Cost Analysis for Intravenous Route of Administration (US$), 2018
Figure 4-7: Global - Rituxan Sales (US$ Billion), 2015-2017
Figure 4-8: Cyclophosphamide - Available Intravenous Powder Concentration (mg/vial), 2018
Figure 4-9: Cyclophosphamide - Available Capsule Concentration (mg/vial), 2018
Figure 4-10: Cyclophosphamide – Dosage Analysis in Initial Treatment Course (mg/kg), 2018
Figure 4-11: Cyclophosphamide – Maximum Dose in Treatment Course (mg/kg), 2018
Figure 4-12: Cyclophosphamide – Dosage Analysis for Diffuse Large B- Cell Lymphoma (mg/m2/Day), 2018
Figure 4-13: Cyclophosphamide - Intravenous Powder Price Analysis by Concentration (mg), 2018
Figure 4-14: Cyclophosphamide - Capsule Price Analysis by Concentration (mg), 2018
Figure 4-15: Doxorubicin - Available Intravenous Powder Concentration (mg), 2018
Figure 4-16: Doxorubicin – Availability in Market by Vial Quantity (2mg/ml), 2018
Figure 4-17: Doxorubicin – Initial Dosage (mg/m2/Dose)
Figure 4-18: Doxorubicin – Maximum Dosage (mg/m2/Dose)
Figure 4-19: Doxorubicin – Duration of Treatment Cycle (Number of Days)
Figure 4-20: Doxorubicin - Intravenous Powder Price Analysis by Concentration (US$), 2018
Figure 4-21: Doxorubicin - Intravenous Solution Price Analysis by Concentration (US$), 2018
Figure 4-22: Vincristine – Dosage Analysis (mg/ml/Week)
Figure 4-23: Vincristine – Availability in Market by Vial Quantity (ml), 2018
Figure 4-24: Vincristine - Intravenous Solution Price Analysis by Concentration (US$), 2018
Figure 4-25: Prednisone – Available Oral Solution by Concentration (ml), 2018
Figure 4-26: Prednisone - Available Oral Tablet by Concentrations (mg), 2018
Figure 4-27: Prednisone - Oral Solution Price Analysis by Concentration (US$), 2018
Figure 4-28: Prednisone - Oral Tablet Cost Price Analysis (US$/100 Tablets), 2018
Figure 5-1: Yescarta – Patent Approval Year in US & Estimate Treatment Cost (US$)
Figure 5-2: Information of Yescarta Drug among the Population (%)
Figure 5-3: Imbruvica – US Patent Approval Year & Patent Expiration Year
Figure 5-4: Imbruvica - 140mg Capsule Price Analysis (US$/Packet), 2018
Figure 5-5: Imbruvica - Treatment Cost Analysis (US$), 2018
Figure 5-6: Imbruvica – Clinical Efficacy by Survival Rate & Survival Response (%), 2018
Figure 5-7: Imbruvica - Global Sales (US$ Billion), 2015 - 2017
Figure 5-8: Rituxan Hycela – Availability by Concentration (ml), 2018
Figure 5-9: Rituxan Hycela – Cell Units in Vial (by Number), 2018
Figure 5-10: Rituxan Hycela – Dosage in CHOP Therapy (mg/Cell Units), 2018
Figure 5-11: Rituxan Hycela – Price Analysis by Concentration (US$/Unit), 2018
Figure 5-12: Rituxan Hycela – Vial Price Analysis (US$), 2018
Figure 6-1: Global - Estimated Number of All New Annual Cancer Cases (%), 2018
Figure 6-2: Estimated New Annual Cases of Blood Cancers, 2018 (%)
Figure 6-3: Distribution of Types of Lymphoma (%)
Figure 6-4: Global - Hodgkin Lymphoma Market Opportunity (US$ Billion), 2017-2024
Figure 6-5: Global- Non-Hodgkin Lymphoma Market Growth Estimation (US$ Billion), 2017-2024
Figure 6-6: Classification of Subtypes of Non-Hodgkin Lymphoma Market (%)
Figure 6-7: Global - Patients Affected by Issues Before, During & After the Treatment (%), 2016
Figure 6-8: Barriers to Adequate Treatment Approach of Diffuse Large B cell Lymphoma (%), 2016
Figure 8-1: Favorable Factors for the Growth of Diffuse Large B cell Lymphoma Market
Figure 8-2: Challenges to the Growth of Diffuse Large B cell Lymphoma Market
Figure 10-1: Global Diffuse Large B Cell Lymphoma Clinical Pipeline by Phase (%), 2018 till 2024
Figure 10-2: Global Diffuse Large B Cell Lymphoma Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 10-3: Global Diffuse Large B Cell Lymphoma Clinical Pipeline by Phase (%),2018 till 2024
Figure 10-4: Global Diffuse Large B Cell Lymphoma Clinical Pipeline by Phase (Number), 2018 till 2024
LIST OF TABLES
Table 3-1: Diagnostic Positron Emission Tomography Scan by Histology
Table 3-2: Standard Regimen of R-CHOP Chemotherapy plus Monoclonal Antibody for 6 Cycles
Table 5-1: Response Rate of Recipients who Received Yescarta Drug in Clinical Trials (%)
Table 5-2: Cost Effective Analysis of Imbruvica Drug
Table 5-3: Response Effective Analysis of Rituxan Hycela Injection in Clinical Trials
Table 9-1: Ongoing PD-1 Inhibitors Clinical Trials Related with Diffuse Large B cell Lymphoma
Table 3-1: Diagnostic Positron Emission Tomography Scan by Histology
Table 3-2: Standard Regimen of R-CHOP Chemotherapy plus Monoclonal Antibody for 6 Cycles
Table 5-1: Response Rate of Recipients who Received Yescarta Drug in Clinical Trials (%)
Table 5-2: Cost Effective Analysis of Imbruvica Drug
Table 5-3: Response Effective Analysis of Rituxan Hycela Injection in Clinical Trials
Table 9-1: Ongoing PD-1 Inhibitors Clinical Trials Related with Diffuse Large B cell Lymphoma
